NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Forecast & News

Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARWR shares have decreased by 1.5% and is now trading at $28.12. View which stocks have been mosted impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its quarterly earnings data on Wednesday, February, 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by $0.07. The biotechnology company had revenue of $29.46 million for the quarter, compared to analysts' expectations of $36.63 million. Arrowhead Pharmaceuticals had a return on equity of 18.21% and a net margin of 32.56%. View Arrowhead Pharmaceuticals' earnings history.

9 analysts have issued twelve-month target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $29.00 to $81.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $62.13 in the next year. This suggests a possible upside of 120.9% from the stock's current price. View analysts' price targets for Arrowhead Pharmaceuticals.

News stories about ARWR stock have trended somewhat positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arrowhead Pharmaceuticals earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutArrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals saw a decrease in short interest in March. As of March 13th, there was short interest totaling 8,270,900 shares, a decrease of 5.2% from the February 27th total of 8,720,000 shares. Based on an average daily trading volume, of 1,587,800 shares, the days-to-cover ratio is currently 5.2 days. Approximately 8.9% of the company's stock are sold short. View Arrowhead Pharmaceuticals' Current Options Chain.

Some companies that are related to Arrowhead Pharmaceuticals include GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Beigene (BGNE), Sarepta Therapeutics (SRPT), Mylan (MYL), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Jazz Pharmaceuticals (JAZZ) and Bausch Health Companies (BHC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Sarepta Therapeutics (SRPT), Bank of America (BAC), salesforce.com (CRM) and Bristol-Myers Squibb (BMY).

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Arrowhead Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (4.06%), FMR LLC (1.85%), Geode Capital Management LLC (1.41%), Fiera Capital Corp (1.34%), Bank of New York Mellon Corp (1.05%) and Norges Bank (1.03%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View institutional ownership trends for Arrowhead Pharmaceuticals.

ARWR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Farallon Capital Management LLC, Candriam Luxembourg S.C.A., Principal Financial Group Inc., Rafferty Asset Management LLC, Goldman Sachs Group Inc., Oak Ridge Investments LLC, and Fiera Capital Corp. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, and Patrick O'brien. View insider buying and selling activity for Arrowhead Pharmaceuticals.

ARWR stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Eagle Asset Management Inc., FMR LLC, Credit Suisse AG, American International Group Inc., Mutual of America Capital Management LLC, Retirement Systems of Alabama, and Geode Capital Management LLC. View insider buying and selling activity for Arrowhead Pharmaceuticals.

Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARWR stock can currently be purchased for approximately $28.12.

Arrowhead Pharmaceuticals has a market capitalization of $2.86 billion and generates $168.80 million in revenue each year. The biotechnology company earns $67.97 million in net income (profit) each year or $0.69 on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe. View additional information about Arrowhead Pharmaceuticals.

The official website for Arrowhead Pharmaceuticals is http://www.arrowheadpharma.com/.

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]